Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Faron Pharmaceuticals Oy (4FR.F) Follow Add holdings 2.4000 -0.0650 (-2.64%) As of 8:05:16 AM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 4FR.F 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 4FR.F View More All News Press Releases SEC Filings Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025 Holding in Company Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress Board Changes Results of the Annual General Meeting, Change of Directors, Decision of the Board Meeting After the AGM Shareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be Elected Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2024 Earnings Call Highlights: Financial Gains and ... Faron presents BEXMAB data at ASH Annual Meeting Faron Pharma secures UK innovation passport for blood cancer immunotherapy Faron Pharmaceuticals reports positive data from MDS trial